IP Litigation Trends: Health Care

Law360, New York (February 14, 2007, 12:00 AM EST) -- Though the battle between pharmaceuticals giants and their generic rivals continued to rage in 2006, it showed signs of slowing down in the latter part of the year as big firms more readily embraced authorized generics as an alternative to litigation, our survey of the top 50 health care companies revealed.

“Most issues between big pharmaceuticals and generics revolve around how they can settle their lawsuits. These companies are most interested in coming up with an amicable resolution. The problem is the Department of Justice doesn’t...
To view the full article, register now.